Zelnorm
NDC 0525-0971
Product Information
Zelnorm is a NDA-approved product labeled by Alfasigma Usa, Inc.. This medication is used by women to treat a certain stomach/intestinal disorder (irritable bowel syndrome with constipation, or IBS-C). It is supplied as a yellow product. This product entry covers the primary NDC 0525-0971 and 3 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
ZEL;6
Code Structure Chart
Product Details
What is NDC 0525-0971?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- TEGASEROD (UNII: 458VC51857)
- TEGASEROD (UNII: 458VC51857) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
- CROSPOVIDONE (UNII: 2S7830E561)
- GLYCERYL DIBEHENATE (UNII: R8WTH25YS2)
- LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)
- HYPROMELLOSES (UNII: 3NXW29V3WO)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 349467 - tegaserod maleate 6 MG Oral Tablet
- RxCUI: 349467 - tegaserod 6 MG Oral Tablet
- RxCUI: 352188 - Zelnorm 6 MG Oral Tablet
- RxCUI: 352188 - tegaserod 6 MG Oral Tablet [Zelnorm]
* Please review the full disclaimer at the bottom of this page.
Patient Education
Tegaserod
Tegaserod is used in women younger than 65 years of age to treat irritable bowel syndrome with constipation (IBS-C; a condition that causes stomach pain or cramps, bloating, and infrequent or difficult passage of stools). Tegaserod is in a class of medications called serotonin agonists. It works by improving muscle movement and increasing production of fluid in the bowels.
[Learn More]
* Please review the full disclaimer at the bottom of this page.